Review



p gl3  (Addgene inc)


Bioz Verified Symbol Addgene inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Addgene inc p gl3
    HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p <t>GL3-basic-luc</t> vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).
    P Gl3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+p+gl3-basic/pGL3-RARE-luciferase+(Plasmid+%2313458)/pmc10218549-226-16-22
    Average 93 stars, based on 46 article reviews
    p gl3 - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "Hepatocyte Nuclear Factor 4α (HNF4α) Plays a Controlling Role in Expression of the Retinoic Acid Receptor β ( RARβ ) Gene in Hepatocytes"

    Article Title: Hepatocyte Nuclear Factor 4α (HNF4α) Plays a Controlling Role in Expression of the Retinoic Acid Receptor β ( RARβ ) Gene in Hepatocytes

    Journal: International Journal of Molecular Sciences

    doi: 10.3390/ijms24108608

    HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p GL3-basic-luc vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).
    Figure Legend Snippet: HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p GL3-basic-luc vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).

    Techniques Used: Transfection, Construct, Plasmid Preparation, Control, Luciferase, Activity Assay

    Mutation of the critical residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human APOC3 and CYP2C9 genes. HepG2 cells were co-transfected with either the p GL3-b-hApoC3 ( A – C ) or p GL3-b-hCYP2C9 ( D – F ) promoter construct together with either hHNF4α, RARα/RXRα, or all three transcription factors, and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for their luciferase activity. The effects of the individual mutant residues in the ligand binding domain of the human HNF4α compared with WT HNF4α on the promoter activity of APOC3 ( B ) or CYP2C9 ( E ) in HepG2 cells treated with either vehicle or 1 μM RA for 24 h. The endogenous HNF4α transcriptional activity toward APOC3 ( C ) and CYP2C9 ( F ) promoters was assessed in HepG2 cells with or without the addition of human HNF4α mutants. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.
    Figure Legend Snippet: Mutation of the critical residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human APOC3 and CYP2C9 genes. HepG2 cells were co-transfected with either the p GL3-b-hApoC3 ( A – C ) or p GL3-b-hCYP2C9 ( D – F ) promoter construct together with either hHNF4α, RARα/RXRα, or all three transcription factors, and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for their luciferase activity. The effects of the individual mutant residues in the ligand binding domain of the human HNF4α compared with WT HNF4α on the promoter activity of APOC3 ( B ) or CYP2C9 ( E ) in HepG2 cells treated with either vehicle or 1 μM RA for 24 h. The endogenous HNF4α transcriptional activity toward APOC3 ( C ) and CYP2C9 ( F ) promoters was assessed in HepG2 cells with or without the addition of human HNF4α mutants. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Techniques Used: Mutagenesis, Ligand Binding Assay, Activation Assay, Transfection, Construct, Luciferase, Activity Assay

    Mutation of the critical amino acid residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human CYP26A1 and RARβ genes in HepG2 cells treated with RA. HepG2 cells grown in 24-well plates were co-transfected with either p GL3-b-hCYP26A1 ( A ) or p GL3-b-hRARβ ( B ) promoters, each with p RLTK as the control, together with either wildtype (WT) HNF4α or its individual mutants (Mutant # 1 to 8), and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for luciferase activity. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.
    Figure Legend Snippet: Mutation of the critical amino acid residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human CYP26A1 and RARβ genes in HepG2 cells treated with RA. HepG2 cells grown in 24-well plates were co-transfected with either p GL3-b-hCYP26A1 ( A ) or p GL3-b-hRARβ ( B ) promoters, each with p RLTK as the control, together with either wildtype (WT) HNF4α or its individual mutants (Mutant # 1 to 8), and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for luciferase activity. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Techniques Used: Mutagenesis, Ligand Binding Assay, Activation Assay, Transfection, Control, Luciferase, Activity Assay

    Related Articles

    Reporter Assay:

    Article Title: DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species.
    Article Snippet: For inducible DHRS13 knockdown, non-targeting and DHRS13-targeting shRNAs were cloned into the pGLTR-X-puro vector obtained from Addgene (#58246, Watertown, MA, USA). .. For the reporter assay, a vector containing the transcription factor response element (retinoic acid receptor response element) was purchased from Addgene (#13458, Watertown, MA, USA) and cloned into the pLL-mCMV-EGFP-PGK-BLAST vector. .. In this study, the following reagents have been used: Dimethyl sulfoxide (D2650, Sigma-Aldrich), All-trans-retinoic acid (R2625, SigmaAldrich), All-trans-retinaldehyde (R2500, Sigma-Aldrich), LY3214996 (27936, Cayman Chemical, Ann Arbor, MI, USA), U-0126 (70970, Cayman Chemical), BCNU (Carmustine) (C0400, Sigma-Aldrich), AGN193109 (5758, Tocris), MitoTEMPOL (18796, Cayman Chemical), ZVAD-FMK (HY-16658B, MedChemExpress, Monmouth Junction, NJ, USA), FCCP (HY-100410, MedChemExpress), Chloroquine (S6999, Selleckchem, Houston, USA), Disulfiram (HY-B0240, MedChemExpress), and Doxycycline hyclate (D9891, Sigma-Aldrich).

    Article Title: DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species
    Article Snippet: For inducible DHRS13 knockdown, non-targeting and DHRS13-targeting shRNAs were cloned into the pGLTR-X-puro vector obtained from Addgene (#58246, Watertown, MA, USA). .. For the reporter assay, a vector containing the transcription factor response element (retinoic acid receptor response element) was purchased from Addgene (#13458, Watertown, MA, USA) and cloned into the pLL-mCMV-EGFP-PGK-BLAST vector. .. In this study, the following reagents have been used: Dimethyl sulfoxide (D2650, Sigma-Aldrich), All- trans -retinoic acid (R2625, Sigma-Aldrich), All- trans -retinaldehyde (R2500, Sigma-Aldrich), LY3214996 (27936, Cayman Chemical, Ann Arbor, MI, USA), U-0126 (70970, Cayman Chemical), BCNU (Carmustine) (C0400, Sigma-Aldrich), AGN193109 (5758, Tocris), MitoTEMPOL (18796, Cayman Chemical), Z-VAD-FMK (HY-16658B, MedChemExpress, Monmouth Junction, NJ, USA), FCCP (HY-100410, MedChemExpress), Chloroquine (S6999, Selleckchem, Houston, USA), Disulfiram (HY-B0240, MedChemExpress), and Doxycycline hyclate (D9891, Sigma-Aldrich).

    Clone Assay:

    Article Title: DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species.
    Article Snippet: For inducible DHRS13 knockdown, non-targeting and DHRS13-targeting shRNAs were cloned into the pGLTR-X-puro vector obtained from Addgene (#58246, Watertown, MA, USA). .. For the reporter assay, a vector containing the transcription factor response element (retinoic acid receptor response element) was purchased from Addgene (#13458, Watertown, MA, USA) and cloned into the pLL-mCMV-EGFP-PGK-BLAST vector. .. In this study, the following reagents have been used: Dimethyl sulfoxide (D2650, Sigma-Aldrich), All-trans-retinoic acid (R2625, SigmaAldrich), All-trans-retinaldehyde (R2500, Sigma-Aldrich), LY3214996 (27936, Cayman Chemical, Ann Arbor, MI, USA), U-0126 (70970, Cayman Chemical), BCNU (Carmustine) (C0400, Sigma-Aldrich), AGN193109 (5758, Tocris), MitoTEMPOL (18796, Cayman Chemical), ZVAD-FMK (HY-16658B, MedChemExpress, Monmouth Junction, NJ, USA), FCCP (HY-100410, MedChemExpress), Chloroquine (S6999, Selleckchem, Houston, USA), Disulfiram (HY-B0240, MedChemExpress), and Doxycycline hyclate (D9891, Sigma-Aldrich).

    Article Title: DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species
    Article Snippet: For inducible DHRS13 knockdown, non-targeting and DHRS13-targeting shRNAs were cloned into the pGLTR-X-puro vector obtained from Addgene (#58246, Watertown, MA, USA). .. For the reporter assay, a vector containing the transcription factor response element (retinoic acid receptor response element) was purchased from Addgene (#13458, Watertown, MA, USA) and cloned into the pLL-mCMV-EGFP-PGK-BLAST vector. .. In this study, the following reagents have been used: Dimethyl sulfoxide (D2650, Sigma-Aldrich), All- trans -retinoic acid (R2625, Sigma-Aldrich), All- trans -retinaldehyde (R2500, Sigma-Aldrich), LY3214996 (27936, Cayman Chemical, Ann Arbor, MI, USA), U-0126 (70970, Cayman Chemical), BCNU (Carmustine) (C0400, Sigma-Aldrich), AGN193109 (5758, Tocris), MitoTEMPOL (18796, Cayman Chemical), Z-VAD-FMK (HY-16658B, MedChemExpress, Monmouth Junction, NJ, USA), FCCP (HY-100410, MedChemExpress), Chloroquine (S6999, Selleckchem, Houston, USA), Disulfiram (HY-B0240, MedChemExpress), and Doxycycline hyclate (D9891, Sigma-Aldrich).

    other:

    Article Title: DHRS13 suppresses differentiation and mitophagy in glioma via retinoic acid and mitochondrial reactive oxygen species
    Article Snippet: Fig. 2F,G: The RARE-driven reporter, derived from an established construct (Addgene #13458), shows a response in shRNA anti-DHRS13 transduced 528NS and HOG-GSC cells comparable to high retinoic acid concentrations (1-3 micromolar).

    Plasmid Preparation:

    Article Title: Angptl5 restricts primitive hematopoiesis by modulating retinoic acid signaling in zebrafish
    Article Snippet: The angptl5:EGFP plasmid was generated by cloning the angptl5 promoter by cloning the upstream 867 bp region of angptl5 gene and EGFP fragment into the Tol2 backbone using a seamless cloning kit (Vazyme). .. For the RARE:EGFP plasmid, the EF1α enhancer-promoter in the PT2AL200R150G transposon vector ( ) was replaced with a trimerized RARE promoter sequence, which was amplified from the pGL3-RARE-luciferase plasmid (Addgene). ..

    Article Title: Vitamin A and its analogues modulate MUFAs metabolism to improve ferroptosis and aging by direct targeting of ACSL3
    Article Snippet: .. The plasmid of pGL3-RARE-luciferase was from T. Michael Underhill (Addgene plasmid # 13458; http://n2t.net/addgene:13458;/RRID:/Addgene_13458 ). .. HEK293T cells were seeded in white 96-well plate. pGL3-RARE-luciferase plasmid at dose of 50 ng per well was transfected into cells with the PolyJetTM reagent (SignaGen).

    Article Title: Vitamin A and its analogues modulate MUFAs metabolism to improve ferroptosis and aging by direct targeting of ACSL3
    Article Snippet: .. The plasmid of pGL3-RARE-luciferase was from T. Michael Underhill (Addgene plasmid # 13458; http://n2t.net/addgene: 13458;/RRID:/Addgene_13458). .. Next cells were stained with 1 μmol/L of FerroOrange (Dojingo, F374) in PBS with indicated compounds for exactly 30 min at 37 ◦ C and 5% CO 2 .

    Sequencing:

    Article Title: Angptl5 restricts primitive hematopoiesis by modulating retinoic acid signaling in zebrafish
    Article Snippet: The angptl5:EGFP plasmid was generated by cloning the angptl5 promoter by cloning the upstream 867 bp region of angptl5 gene and EGFP fragment into the Tol2 backbone using a seamless cloning kit (Vazyme). .. For the RARE:EGFP plasmid, the EF1α enhancer-promoter in the PT2AL200R150G transposon vector ( ) was replaced with a trimerized RARE promoter sequence, which was amplified from the pGL3-RARE-luciferase plasmid (Addgene). ..

    Amplification:

    Article Title: Angptl5 restricts primitive hematopoiesis by modulating retinoic acid signaling in zebrafish
    Article Snippet: The angptl5:EGFP plasmid was generated by cloning the angptl5 promoter by cloning the upstream 867 bp region of angptl5 gene and EGFP fragment into the Tol2 backbone using a seamless cloning kit (Vazyme). .. For the RARE:EGFP plasmid, the EF1α enhancer-promoter in the PT2AL200R150G transposon vector ( ) was replaced with a trimerized RARE promoter sequence, which was amplified from the pGL3-RARE-luciferase plasmid (Addgene). ..



    Similar Products

    90
    Promega plasmid p gl3-basic
    Plasmid P Gl3 Basic, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+p+gl3-basic/gl3+basic+vector/pmc11739467-458-21-24
    Average 90 stars, based on 1 article reviews
    plasmid p gl3-basic - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    90
    Igene Biotechnology Inc human gsdme promoter plasmid (p-gl3-basic-homogsdme-promoter)
    Human Gsdme Promoter Plasmid (P Gl3 Basic Homogsdme Promoter), supplied by Igene Biotechnology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+p+gl3-basic/human+gsdme+promoter+plasmid++p+gl3+basic+homogsdme+promoter+/pm39592733-87-3-16
    Average 90 stars, based on 1 article reviews
    human gsdme promoter plasmid (p-gl3-basic-homogsdme-promoter) - by Bioz Stars, 2026-11
    90/100 stars
      Buy from Supplier

    93
    Addgene inc p gl3
    HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p <t>GL3-basic-luc</t> vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).
    P Gl3, supplied by Addgene inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/plasmid+p+gl3-basic/pGL3-RARE-luciferase+(Plasmid+%2313458)/pmc10218549-226-16-22
    Average 93 stars, based on 1 article reviews
    p gl3 - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p GL3-basic-luc vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).

    Journal: International Journal of Molecular Sciences

    Article Title: Hepatocyte Nuclear Factor 4α (HNF4α) Plays a Controlling Role in Expression of the Retinoic Acid Receptor β ( RARβ ) Gene in Hepatocytes

    doi: 10.3390/ijms24108608

    Figure Lengend Snippet: HNF4α regulates the promoter of the RARβ gene in HepG2 cells. HepG2 cells in 24-well plates were co-transfected for 24 h with a fragment of the human RARβ promoter expanding from −1.7 kbp from transcription start site to +0.217 kpb, as the full length promoter construct, in p GL3-basic-luc vector together with p RLTK plasmid containing Renilla-luc, as the control, and with either human HNF4α, RARα/RXRα, or all three transcription factors, and then treated further either without ( A ) or with RA for 1 to 24 h, after which the cells were collected to assay for luciferase activity. HNF4α alone or with RARα/RXRα suppressed the promoter activity of the human RARβ gene in the cells treated without RA ( A ), but upregulated the promoter when the cells were treated with RA following transfection ( B ). HNF4α regulates the promoter of the mouse RARβ gene in HepG2 cells ( C ). It suppresses the promoter activity of the mouse gene (empty bars in C) in HepG2 cells treated with the vehicle, but it increases the promoter activity in the cells treated with RA (black bar in C).

    Article Snippet: Construction of the plasmid vectors including p GL3-Basic-hCYP26A1-E4-luc (submitted to addgene.org), p GL3-Basic-hRARβp-luc (human RARβ2 promoter), p GL3-Basic-hCYP2C9p-luc, p cDNNA3.1-hRARα.hRXRα (submitted to addgene.org), and p cDNA3.1-hHNF4α were reported previously [ , , , , ].

    Techniques: Transfection, Construct, Plasmid Preparation, Control, Luciferase, Activity Assay

    Mutation of the critical residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human APOC3 and CYP2C9 genes. HepG2 cells were co-transfected with either the p GL3-b-hApoC3 ( A – C ) or p GL3-b-hCYP2C9 ( D – F ) promoter construct together with either hHNF4α, RARα/RXRα, or all three transcription factors, and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for their luciferase activity. The effects of the individual mutant residues in the ligand binding domain of the human HNF4α compared with WT HNF4α on the promoter activity of APOC3 ( B ) or CYP2C9 ( E ) in HepG2 cells treated with either vehicle or 1 μM RA for 24 h. The endogenous HNF4α transcriptional activity toward APOC3 ( C ) and CYP2C9 ( F ) promoters was assessed in HepG2 cells with or without the addition of human HNF4α mutants. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Journal: International Journal of Molecular Sciences

    Article Title: Hepatocyte Nuclear Factor 4α (HNF4α) Plays a Controlling Role in Expression of the Retinoic Acid Receptor β ( RARβ ) Gene in Hepatocytes

    doi: 10.3390/ijms24108608

    Figure Lengend Snippet: Mutation of the critical residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human APOC3 and CYP2C9 genes. HepG2 cells were co-transfected with either the p GL3-b-hApoC3 ( A – C ) or p GL3-b-hCYP2C9 ( D – F ) promoter construct together with either hHNF4α, RARα/RXRα, or all three transcription factors, and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for their luciferase activity. The effects of the individual mutant residues in the ligand binding domain of the human HNF4α compared with WT HNF4α on the promoter activity of APOC3 ( B ) or CYP2C9 ( E ) in HepG2 cells treated with either vehicle or 1 μM RA for 24 h. The endogenous HNF4α transcriptional activity toward APOC3 ( C ) and CYP2C9 ( F ) promoters was assessed in HepG2 cells with or without the addition of human HNF4α mutants. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Article Snippet: Construction of the plasmid vectors including p GL3-Basic-hCYP26A1-E4-luc (submitted to addgene.org), p GL3-Basic-hRARβp-luc (human RARβ2 promoter), p GL3-Basic-hCYP2C9p-luc, p cDNNA3.1-hRARα.hRXRα (submitted to addgene.org), and p cDNA3.1-hHNF4α were reported previously [ , , , , ].

    Techniques: Mutagenesis, Ligand Binding Assay, Activation Assay, Transfection, Construct, Luciferase, Activity Assay

    Mutation of the critical amino acid residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human CYP26A1 and RARβ genes in HepG2 cells treated with RA. HepG2 cells grown in 24-well plates were co-transfected with either p GL3-b-hCYP26A1 ( A ) or p GL3-b-hRARβ ( B ) promoters, each with p RLTK as the control, together with either wildtype (WT) HNF4α or its individual mutants (Mutant # 1 to 8), and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for luciferase activity. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Journal: International Journal of Molecular Sciences

    Article Title: Hepatocyte Nuclear Factor 4α (HNF4α) Plays a Controlling Role in Expression of the Retinoic Acid Receptor β ( RARβ ) Gene in Hepatocytes

    doi: 10.3390/ijms24108608

    Figure Lengend Snippet: Mutation of the critical amino acid residues present in the ligand binding domain of human HNF4α suppresses transcription activation of the promoters of human CYP26A1 and RARβ genes in HepG2 cells treated with RA. HepG2 cells grown in 24-well plates were co-transfected with either p GL3-b-hCYP26A1 ( A ) or p GL3-b-hRARβ ( B ) promoters, each with p RLTK as the control, together with either wildtype (WT) HNF4α or its individual mutants (Mutant # 1 to 8), and then treated with either vehicle or 1 µM RA for 24 h, after which the cells were assayed for luciferase activity. Data from each bar represent the mean of n = 3 wells ± SD. HNF4α mutant #’s are as follows: (1) S190K, (2) 191MK, (3) R221G, (4) L228K, (5) L229K, (6) R235G, (7) I347K, and (8) I355K.

    Article Snippet: Construction of the plasmid vectors including p GL3-Basic-hCYP26A1-E4-luc (submitted to addgene.org), p GL3-Basic-hRARβp-luc (human RARβ2 promoter), p GL3-Basic-hCYP2C9p-luc, p cDNNA3.1-hRARα.hRXRα (submitted to addgene.org), and p cDNA3.1-hHNF4α were reported previously [ , , , , ].

    Techniques: Mutagenesis, Ligand Binding Assay, Activation Assay, Transfection, Control, Luciferase, Activity Assay